Ann: Class action settlement, page-61

What is going on indeed Raj. I have no idea as all the research and information I have collected seems to point to an upside in price not a downside.

Here's some information you may like to investigate:

• Wilsons have reiterated their buy recommendations after the class settlement and have not moved their target price.
• On the 3rd of July AHIP (Association of Health Insurers) replied to congress on contraceptive coverage and expressed their willingness to collaborate with congress to make the most recent guidance happen. If you recall the latest guidance mandates that all FDA approved contraceptive products must be supplied without cost sharing if there is no therapeutic equivalent. This will in time bring all the insurers in line with the mandate.
• Also on the 26/6/2024 post Gedeon Richter acquisition of Mithra assets, GR held a video conference with their shareholders which gave a comprehensive view of the transaction and what they expect to do different from Mithra. It goes for nearly an hour but well worth listening to, particularly the QA. Here's the link
• https://www.gedeonrichter.com/-/media/sites/hq/documents/investors/presentations/en/2024/whc-presentation-for-investors-20240625.mp4

My main points of interest of the video call regarding how it might affect MYX are:

• GR was aware for a number of years that Mithra's business model was unsustainable.Mithra thought they had a blockbuster drug and compound and behaved accordingly from the start (with crazy contracts and expectations of partners), they behaved like they were running Nvidia instead of a company going over the edge.
• There was no other bidder for the assets, although there were considerable claims from suppliers, secured lenders, bankruptcy lawyers, partners and employees. They thought they picked up the assets very cheaply.
• GR has more sober expectations of the products and are working with partners to simplify the contracts and achieve success.
• GR held meeting(s) with MYX before they became owners of the product and discussed the road blocks preventing MYX from achieving quicker penetration of Nextstellis. Now as owners of the product they can offer assistance to remove some of these impediments (undisclosed). They see high upside for Nexstellis in the US.
• Donesta FDA submission is still some time away and they're searching for a US commercial partner but it's not a pressing concern as it was for Mithra.
• With respect to their US presence, I got the impression that all they want to do is find partner(s) to commercialise their products.

Cheers